26.12

3.67% 0.83

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is traded at $26.12, with a volume of 433.41K. It is up +3.67% in the last 24 hours and down -18.40% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Previous Close:

$25.29

Open:

$25

24h Volume:

433.41K

Relative Volume:

0.53

Market Cap:

$1.56B

Revenue:

Net Income/Loss:

$-131.11M

P/E Ratio:

-12.01

EPS:

-2.1745

Net Cash Flow:

$-102.47M

1W Performance:

-0.12%

1M Performance:

-18.40%

6M Performance:

-9.96%

1Y Performance:

+144.34%

1-Day Range:

$24.98

$27.05

1-Week Range:

$24.61

$27.05

52-Week Range:

$9.96

$40.65

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(619) 728-4760

Address

2656 STATE STREET, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

TYRA's Discussions on Twitter

Compare TYRA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TYRA Tyra Biosciences Inc	26.11	1.51B	0	-131.11M	-102.47M	-2.1745
VRTX Vertex Pharmaceuticals Inc	515.52	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.63	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.26	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.10	39.31B	5.76B	514.49M	1.10B	4.4813

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Guggenheim	Buy
Apr-06-26	Initiated	Canaccord Genuity	Buy
Feb-24-26	Initiated	Cantor Fitzgerald	Overweight
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight
Sep-03-25	Initiated	Raymond James	Strong Buy
May-21-25	Resumed	Piper Sandler	Overweight
Jan-07-25	Initiated	UBS	Buy
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy
Aug-15-24	Initiated	Piper Sandler	Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

01:42 AM

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%Time to Buy? - marketbeat.com

01:42 AM

Aug 15, 2026

Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA - marketbeat.com

Aug 15, 2026

Aug 14, 2026

TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake - Stock Titan

Aug 14, 2026

Tyra Biosciences examines FGFR3 gene impact on cell growth disorders - Traders Union

Aug 14, 2026

Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Avoiding Lag: Real-Time Signals in (TYRA) Movement - Stock Traders Daily

Aug 13, 2026

Aug 11, 2026

Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside - TradingView

Aug 11, 2026

BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39 - Moomoo

Aug 11, 2026

BofA Adjusts Price Target on Tyra Bioscience to $39 From $42 - marketscreener.com

Aug 11, 2026

Aug 10, 2026

TYRA's dabogratinib trial in 2026 could validat... - Pluang

Aug 10, 2026

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet (NASDAQ:TYRA) - Seeking Alpha

Aug 10, 2026

Aug 07, 2026

HC Wainwright Brokers Lower Earnings Estimates for TYRA - marketbeat.com

Aug 07, 2026